Nakamura K, Kubo A, Hosokawa S, Nagaike K, Hashimoto S
Department of Radiology, School of Medicine, Keio University, Tokyo, Japan.
Oncology. 1993;50(1):35-40. doi: 10.1159/000227144.
We studied the potential of alpha-interferon (IFN-alpha) to enhance alpha-fetoprotein (AFP) and thus alter the localization of 125I-labeled antibody to the human hepatoma xenograft in athymic mice using monoclonal antibody (MAb) 19F12, which recognized AFP on the surface of human hepatoma cells. Treatment of the human hepatoma cell NuE with IFN-alpha increased the surface expression of AFP 2.4-fold in an IFN-dose-dependent manner. The IFN-alpha treatment substantially increased (2.7-fold) the localization of 125I-labeled 19F12 to NuE xenografts in athymic mice. The increase in localization of 125I-labeled 19F12 was dependent on the circulating plasma IFN levels. Our experimental results suggested that IFN-alpha could act as a potent modulator of the cellular antigen AFP, and be used to enhance the targeting of a conjugated MAb to hepatoma cell populations.
我们使用识别人类肝癌细胞表面甲胎蛋白（AFP）的单克隆抗体（MAb）19F12，研究了α-干扰素（IFN-α）增强甲胎蛋白（AFP）从而改变无胸腺小鼠体内125I标记的抗人肝癌异种移植抗体定位的潜力。用IFN-α处理人肝癌细胞NuE，可使AFP的表面表达以IFN剂量依赖的方式增加2.4倍。IFN-α处理显著增加了（2.7倍）无胸腺小鼠体内125I标记的19F12对NuE异种移植瘤的定位。125I标记的19F12定位的增加依赖于循环血浆中的IFN水平。我们的实验结果表明，IFN-α可作为细胞抗原AFP的有效调节剂，并可用于增强偶联单克隆抗体对肝癌细胞群体的靶向作用。
